Canadian Money Brief | October 19, 2026 CFB Wainwright Fire: What We Know and How to Help Without Getting Scammed Four Canadian soldiers are dead and 39 people were hurt after a grass fire overtook a live-fire training exercise in Alberta. When tragedy hits, Canadians want to help. Scammers know it. What happened On Saturday, October 17, a fire ignited in a training area at Canadian Forces Base Wainwright, about 200 km southeast of Edmonton. Officials say it began as a grass fire during training that included grenades and live ammunition. Military leaders said the fire was known to range control for hours and was believed to be contained enough for training to continue. Then the wind turned. Reporting from Al Jazeera and ABC News describes gusts jumping from about 50 km/h to as high as 96 km/h, pushing the flames toward soldiers and their administrative area. Defence officials said 84 members of the Princess Patricia's Canadian Light Infantry were in the training area. Four servi...
Alzheimer’s vaccines get a boost from new drug approval
After decades of disappointment and controversy, the field of Alzheimer’s disease research has finally seen a breakthrough with the approval of the first drug that targets the underlying pathology of the condition.
Aducanumab, a monoclonal antibody that clears amyloid plaques from the brain, was granted accelerated approval by the US Food and Drug Administration in June 2021, despite mixed results from clinical trials and objections from some experts.
The drug’s approval has rekindled interest in other therapeutic approaches that aim to prevent or slow down the progression of Alzheimer’s, such as vaccines that stimulate the immune system to attack amyloid or tau, another protein that accumulates in the brains of people with the disease.
Several vaccine candidates are currently in various stages of development and testing, and some researchers are optimistic that they could offer a more effective and convenient way to treat Alzheimer’s than infusions of antibodies.
Comments
Post a Comment